

Form PTO-449 JUL 02 2004	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00931	Appln. No.: 10/782,337
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Attach several sheets if necessary)		Applicant Hector F. DeLuca et al	
		Filing Date February 19, 2004	Group Art Unit 1614 1616

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,777,163	10/11/1988	Bosies et al				
	5,587,497	12/24/1996	DeLuca et al				
	5,843,928	12/01/1998	DeLuca et al				
	6,313,119	11/06/2001	Peyman et al				
	6,638,540	10/28/2003	Mühlbauer				

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					Yes	No	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
	The Merck Manual, Sixteenth Edition, 1992, pg. 1357.
	Boris et al, "Relative Activities of Some Metabolites and Analogs of Cholecalciferol in Stimulation of Tibia Ash Weight in Chicks Otherwise Deprived of Vitamin D," Vitamin D Metabolites, Analogs and Bone Ash, 1976, pp. 194-198.
	Hedlund et al, "Increased Incidence of Hip Fracture in Osteoporotic Women Treated with Sodium Fluoride," Journal of Bone and Mineral Research, Vol. 4, No. 2, 1989, pp. 223-225.
	Holick et al, Harrison's Principle of Internal Medicine, 13th Ed. 1994, pp. 2137-2151.
	Jensen et al, "Treatment of Post Menopausal Osteoporosis, A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D-3 and Calcium," Clinical Endocrinology, 16, 1982, pp. 515-524
	Meunier, "Evidence-Based Medicine and Osteoporosis: A Comparison of Fracture Risk Reduction Data from Osteoporosis Randomised Clinical Trials," IJCP, Vol. 53, No. 2, March, 1999.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00931	Appln. No.: 10/782,337
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hector F. DeLuca et al	
		Filing Date February 19, 2004	Group Art Unit 1614 1616

	Nordin et al, "The Metabolic Basis of Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp.23-36.
	Ott et al, "Calcitriol Treatment is not Effective in Postmenopausal Osteoporosis," Annals of Internal Medicine, Vol. 110, No. 4, February 15, 1989, pp. 267-274.
	Peck, "The Pathogenesis of Postmenopausal Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp. 3-6.
503	Riggs et al, "Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures without Commensurate Increases in Bone Density," Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, pp. 11-13.
	Riggs et al, "Causes of Age-Related Bone Loss and Fractures," Osteoporosis: Physiological Basis, Assessment, and Treatment, 1990, pp. 7-16.
	Christensen, Abstract PMID: 6795047, "Effect of 1,25-Dihydroxy-Vitamin D3 in Itself or Combined with Hormone Treatment in Prevent Postmenopausal Osteoporosis," Eur. J. Clin. Invest., August 11, 1981, Vol. 11, No. 4.
	Klein, "Nutritional Rickets and Osteomalacia," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 301-305.
	Kleerekoper, "Treatment of Osteoporosis with Sodium Fluoride Alternating with Calcium and Vitamin D," Osteoporosis: Recent Advances in Pathogenesis and Treatment, 1981, pp. 441-448.
	Sarkar, "Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy," Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, pp. 1-10.
	Cummings et al, "Improvement in Spine Bone Density and Reduction in Risk of Vertebral Fractures During Treatment with Antiresorptive Drugs," The American Journal of Medicine, Vol. 112, 2002, pp. 281-289.
	Sudhaker Rao et al, "Metabolic Bone Disease in Gastrointestinal Hepatobiliary, and Pancreatic Disorders," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 306-311.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00931	Appl. No.: 10/782,337
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hector F. DeLuca et al	
		Filing Date February 19, 2004	Group Art Unit 1614 1616

	Watts et al, "Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis," The New England Journal of Medicine, Vol. 323, No. 2, July 12, 1990, pp. 73-79.
503	Harris, "Four-Year Study of Intermittent Cyclic Etidronate Treatment of Postmenopausal Osteoporosis: Three Years of Blinded Therapy Followed by One Year of Open Therapy," The American Journal of Medicine, Vol. 95, December 1993, pp. 557-567.

EXAMINER	Sabiha Aziz	DATE CONSIDERED	9/26/2004
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to client.			